Evidence map›Paper›PMID 37938539›Full record

ReviewDrug safety2024

Validation of a Natural Language Machine Learning Model for Safety Literature Surveillance.

Jiyoon Park, Malek Djelassi, Daniel Chima, Robert Hernandez, Vladimir Poroshin, Ana-Maria Iliescu, Douglas Domalik, Noel Southall

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drug safety, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiyoon ParkGlobal Patient Safety, Chief Medical Office, AstraZeneca, Gaithersburg, MD, USA.
Malek DjelassiEnterprise AI Services, IGNITE IT, AstraZeneca, Mölndal, Sweden.
Daniel ChimaGlobal Patient Safety, Chief Medical Office, AstraZeneca, Gaithersburg, MD, USA.
Robert HernandezEnterprise AI Services, IGNITE IT, AstraZeneca, Cambridge, UK.
Vladimir PoroshinEnterprise AI Services, IGNITE IT, AstraZeneca, Cambridge, UK.
Ana-Maria IliescuGlobal Patient Safety, Chief Medical Office, AstraZeneca, Mölndal, Sweden.
Douglas DomalikGlobal Patient Safety, Chief Medical Office, AstraZeneca, Gaithersburg, MD, USA.
Noel SouthallGlobal Patient Safety, Chief Medical Office, AstraZeneca, Gaithersburg, MD, USA. noel.southall@astrazeneca.com.ORCID 0000-0003-4500-880X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAs part of routine safety surveillance, thousands of articles of potential interest are manually triaged for review by safety surveillance teams. This manual triage task is an interesting candidate for automation based on the abundance of process data available for training, the performance of natural language processing algorithms for this type of cognitive task, and the small number of safety signals that originate from literature review, resulting in its lower risk profile. However, deep learning algorithms introduce unique risks and the validation of such models for use in Good Pharmacovigilance Practice remains an open question.

objectiveQualifying an automated, deep learning approach to literature surveillance for use at AstraZeneca.

methodsThe study is a prospective validation of a literature surveillance triage model, comparing its real-world performance with that of human surveillance teams working in parallel. The biggest risk in modifying this triage process is missing a safety signal (resulting in model false negatives) and hence model recall is the main evaluation metric considered.

resultsThe model demonstrates consistent global performance from training through testing, with recall rates comparable to that of existing surveillance teams. The model is accepted for use specifically for those products where non-inferiority to the manual process is rigorously demonstrated.

conclusionCharacterizing model performance prospectively, under real-world conditions, allows us to thoroughly examine model consistency and failure modes, qualifying it for use in our surveillance processes. We also identify potential future improvements and recognize the opportunity for the community to collaborate on this shared task.

Indexed as

AlgorithmsMachine LearningAutomationHumansNatural Language ProcessingPharmacovigilance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.